Introduction
Head and neck squamous cell carcinoma (HNSCC), with 500,000 newly diagnosed cases yearly, 1 is a challenge for clinicians since radical surgery is the cornerstone treatment for HNSCC; however, the complex anatomy of the head and neck complicates surgical treatment. Traditional radiotherapy may sometimes be applied in HNSCC patients, but this kind of treatment may further worsen their quality of life. Even with multidisciplinary treatment, most HNSCC patients finally die of cancer metastasis. Currently, survival rates of 61% and 50% are observed for HNSCC patients at 5 years and 10 years, respectively. 2 Thus, development of a new regimen to prevent HNSCC metastasis should be prioritized to improve the survival.
Since the hormone-like role of vitamin D has been discovered, a variety of nonmineral functions of vitamin D have been demonstrated. 1α,25(OH) 2 D 3 , the active form of vitamin D, has been widely studied in anticancer research category due to the prodifferentiation, proapoptosis, antiangiogenesis, and antiproliferation effects of 1α,25(OH) 2 D 3 noted in the past decades. 3, 4 To exert its hormone-like functions, 1α,25(OH) 2 D 3 needs to bind with vitamin D receptor (VDR), which has been shown to exist in a variety of tissues in humans, indicating that 1α,25(OH) 2 9,10 and much more resistance to CYP24A-mediated degradation, 11 suggesting that MART-10 is a potential vitamin D analog for cancer treatment. So far, our group has demonstrated that MART-10 exerts more potent anticancer growth effect than 1α,25(OH) 2 D 3 in a number of cancers [12] [13] [14] and is active in vivo without inducing hypercalcemia. 15 MART-10 has further been demonstrated to attenuate the metastatic potential of anaplastic thyroid cancer, breast cancer, and pancreatic cancer. [16] [17] [18] We have previously shown that MART-10 could effectively repress cancer cell growth in HNSCC. 19 Since metastasis is the main cause of poor prognosis of HNSCC, in this study, we aimed to investigate the effect of MART-10 on HNSCC metastatic potential to further justify the clinical application of MART-10 for HNSCC treatment. 
Materials and methods

Matrigel invasion assay
FaDu or SCC-25 cells were pretreated with indicated concentrations of 1α,25(OH) 2 D 3 or MART-10. The assay was performed as previously described. 16 The invading cells were fixed by 4% paraformaldehyde (0.4% NaOH, 4% paraformaldehyde, and 3.8% hydrated sodium borate, pH 9.5). The invading cells were digitally photographed and counted under the microscope (IX71; Olympus Corporation, Tokyo, Japan). Experiments were performed in triplicates and repeated at least three times.
gelatin zymography
After 2 days of indicated 1α,25(OH) 2 D 3 or MART-10 treatment, the conditioned media were run under nonreducing conditions in 10% sodium dodecyl sulfate-polyacrylamide gels containing 2 mg/mL gelatin (Chemicon International Inc., Temecula, CA, USA). The detailed procedures were as described previously. 16 
Western blot
The detailed procedures for Western blot were described previously. 16 The antibodies used in this experiment were monoclonal antibodies against E-cadherin (1:1,000, #3195; Cell Signaling Technology, Irvine, CA, USA), N-cadherin (1:1,000, #13116; Cell Signaling Technology), Snail (1:1,000, #3879; Cell Signaling Technology), Slug (1:1,000, #9585; Cell Signaling Technology), Twist (1:400, ab49254; Abcam, Cambridge, UK), MMP-2 (1:1,000, #13132; Cell Signaling Technology), and MMP-9 (1:1,000, #13667; Cell Signaling Technology). The blots were detected with enhanced chemiluminescence reagents (WBKLS0500; EMD Millipore, Billerica, MA, USA). Membranes were detected with VersaDoc™ Imaging System (Bio-Rad Laboratories Inc., Hercules, CA, USA).
statistics method
The data from each group were compared by Student's t-test. P-value ,0.05 was considered as a significant difference. The program of Excel 2010 was used to perform the statistics. 
Result
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expressions in FaDu cells
Since MMP-2 and MMP-9 function as two important proteins to digest extracellular matrix to facilitate cell invasion, the intracellular and extracellular MMP-2 and MMP-9 were thus evaluated. Figure 5A and B shows that the intracellular MMP-9 expression, but not MMP-2, in FaDu cells was repressed by both 1α,25(OH) 2 D 3 and MART-10 at the concentration of 10 −7 M. The extracellular MMP-2 and MMP-9 activities were measured by zymography assay. Figure 5C reveals that the extracellular MMP-9 activity was attenuated in FaDu cells as treated 1α,25(OH) 2 D 3 or MART-10.
Discussion
The higher potency of MART-10 than 1α,25(OH) 2 D 3 could be mainly attributed to two reasons. The first is that MART-10 is a poor substrate to CYP24A1, the main enzyme to catabolize 1α,25(OH) 2 D 3 in humans, in a cell-free reconstituted system, 20 which is also supported by a docking analysis showing that 24 hydroxylation of MART-10 is not as easy as that of 1α,25(OH) 2 D 3 . 21 The higher resistance to CYP24A1 degradation indicates that MART-10 could act longer. The second is the higher VDR-binding affinity of MART-10 than 1α,25(OH) 2 D 3 , which was confirmed by the X-ray crystallographic structure of MART-10 complex bound with VDR. 9 Since most 1α,25(OH) 2 D 3 -mediated genomic functions are VDR dependent, the higher VDR-binding affinity of MART-10 reasonably induces higher VDR transactivation. Collectively, MART is expected to have a much more potent effect than 1α,25(OH) 2 D 3 .
In this study, we showed that the newly synthesized 1α,25(OH) 2 D 3 analog, MART-10, exhibited more potent effect than 1α,25(OH) 2 D 3 on attenuation of HNSCC metastatic potential through EMT repression, which was implemented by reversing cadherin switch (upregulation of E-cadherin and downregulation of N-cadherin), inhibition of Snail, Twist, and MMP-9. Given that MART-10 has already been proved to effectively repress HNSCC cell growth, 19 MART-10 should be deemed as a promising drug for HNSCC treatment.
Cancer metastasis is the cause of cancer-related death. The first step of cancer metastasis is tumor cell dissemination, which is triggered by a decrease in cell-cell adhesion and an increase in cell motility and invasiveness, thus enabling tumor cells to detach from the primary lesions, invade through the surrounding matrix, and migrate to other sites. 22 To achieve this, epithelial cancer cells need to go through one process to become invasive, which is EMT. EMT is a process during which epithelial cells transform into mesenchymal-like cells and is important for the development of normal tissues. 23 However, EMT could be reactivated by cancer cells to obtain motility and become invasive. 24 In addition, EMT is able to render tumor cells more resistant to chemotherapies 25, 26 and 
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MarT-10 suppresses hnscc cell metastasis radiotherapies, 27 which further worsens the prognosis. EMT process in cells is well orchestrated and could be regulated transcriptionally, translationally, or posttranslationally. 23 Regarding transcriptional regulation, Snail, Slug, Zeb1/2, and Twist have been implicated in triggering EMT process. 28 Our result revealed that Snail and Twist expressions in FaDu cells were inhibited by 10 −7 M 1α,25(OH) 2 D 3 and MART-10 ( Figure 3) , suggesting that both 1α,25(OH) 2 D 3 and MART-10 could repress EMT process in HNSCC cells, leading to the attenuation of migration and invasion, as shown in Figures 1 and 2 .
Another hallmark of EMT is the "cadherin-switch", referring to the downregulation of E-cadherin and upregulation of N-cadherin. 13, 14 Cadherin belongs to one kind of cell adhesion molecules, which plays a vital role in maintaining the structures of cells and tissues. 29 Upregulation of E-cadherin is able to increase cell-cell adhesion. On the contrary, downregulation of E-cadherin could make cancer cells detach from the primary sites, leading to metastasis. Low E-cadherin expression has been linked with poor prognosis or advanced stage disease of cancers. [30] [31] [32] Unlike E-cadherin, N-cadherin functions to decrease cell-cell adhesion, and thus aberrant expression of N-cadherin has been reported to link with increased cancer invasiveness. 33, 34 The finding that both 1α,25(OH) 2 D 3 and MART-10 could upregulate E-cadherin expression while inhibiting N-cadherin expression in FaDu cells further demonstrates that 1α,25(OH) 2 D 3 and MART-10 are able to repress EMT process in FaDu cells (Figure 4) .
To move from one place to another, cancer cells need to digest the surrounding tissues. MMPs are collagenases functioning to digest the basement membrane. It has been reported that serum MMP-2 and MMP-9 levels are higher in laryngeal SCC patients, 35 and serum vitamin D level has been found to be reversely associated with serum MMP-2 and MMP-9 levels. 36 Our result shows that intracellular MMP-9 expression and extracellular MMP-9 activity of FaDu cells were inhibited by 1α,25(OH) 2 D 3 and MART-10 ( Figure 5 ), leading to the less-invasive phenotype noted in Figure 1 . Of note, MMP-2 expression and activity were not influenced by 1α,25(OH) 2 D 3 and MART-10.
Conclusion
Our result indicates that the newly synthesized 1α,25(OH) 2 D 3 analog, MART-10, is an effective drug to inhibit HNSCC cell metastasis to a greater extent than 1α,25(OH) 2 D 3 . 1α,25(OH) 2 D 3 and MART-10 repressed Snail and Twist expressions and reversed cadherin switch in FaDu cells, indicating that both drugs attenuated EMT process in FaDu cells. In addition, intracellular MMP-9 expression and extracellular MMP-9 activity were inhibited by both drugs. Adding that MART-10 has been previously proved to be able to repress HNSCC cell growth, our current data strongly suggest that MART-10 should be deemed as a promising agent for HNSCC treatment. Further in vivo studies are warranted.
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